http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2568680-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5a31d29d88179e4188657a305be08f3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F5-025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F5-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-69 |
| filingDate | 2011-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_275871b4d6994890ee48e82f058ffd63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d263190cfeb1233467622496f1bf4f0 |
| publicationDate | 2016-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2568680-T3 |
| titleOfInvention | Borates as arginase inhibitors |
| abstract | A compound according to Formula I, ** Formula ** wherein R1 is selected from the group consisting of -OH, ORa, and NRbRc; Ra is selected from the group consisting of hydrogen, straight or branched chain (C1-C6) alkyl, (C3-C8) cycloalkyl, (C3-C14) aryl, (C3-C14) heterocycloalkyl (C1-C6) alkylene - , heteroaryl (C3-C14) -alkylene (C1-C6) -, and aryl (C3-C14) alkylene (C1-C6) -; Rb and Rc are each independently selected from the group consisting of H, -OH, linear or branched (C1-C6) alkyl, -SO2-C1-C6 alkyl, aryl (C3-C14) -SO2-, heterocycloalkyl ( C3-C14) -C1-C6 alkylene -, and (C3-C14) -C1-C6 -alkylene heteroaryl; R2 is selected from the group consisting of H, linear or branched (C1-C6) alkyl, and (C1-C6) -C (O) - alkyl; W, X, Y, and Z are each independently selected from the group consisting of a link, -C (R ') (R' '') -, - C (R '' ') 2-, -CR "' -, -NR "'-, -N-, -O-, -C (O) -, and -S-, where no more than three of W, X, Y, and Z simultaneously represent a link; and neither of two adjacent members W, X, Y, and Z are simultaneously -O-, -S-, -N-, or -NR '' '-; l, m, n and p independently are integers between 0 and 2 inclusive, where at least one of l, m, n, or p is not 0; optionally represents one or more double bonds; R3 and R4 are each independently selected from hydrogen, linear or branched (C1-C6) alkyl, and C (O) -R ', or R3 and R4 together with the boron atom to which they are attached form a 5- ring or 6-members that is fully saturated, or partially saturated; D is selected from the group consisting of linear or branched (C3-C5) alkylene, linear or branched (C2-C8) alkenylene, linear or branched (C2-C8) alkynylene, arylene (C3-C14), and cycloalkylene (C3- C14), where one or more groups -CH2- in D are optionally and independently replaced with a structural unit selected from the group consisting of O, NR ', S, SO, SO2, and CR'R "; or where any of the two adjacent -CH2- groups optionally represent two members of a (C3-C14) cycloalkylene group; and where neither of the two adjacent -CH2- groups simultaneously represent O, NR ', S, SO, or SO2; R' , R "and R" 'are each independently selected from the group consisting of H, OH, S (O) Rd, S (O) 2Rd, (C1-C8) alkyl, aryl (C3-C6), -NH2, -NH (C1-C6) alkyl, -N [(C1-C6) alkyl] 2, -C (O) NRdRe, -C (O) (C1-C6) alkyl, -C (O) aryl (C3-C14) ), -C (O) (C1-C6) alkyl, -C (O) O-aryl (C3-C14), cycloalkyl (C3-C6), heterocycloalkyl (C3-C14), - C (O) heterocycloalkyl (C3 -C 14), heteroaryl (C3-C14), aryl (C3-C14) -alkylene (C1-C6) -, -C (O) aryl (C3-C14) -alkylene (C1-C6) -, -C (O) aryl (C3-C14), cycloalkyl (C3-C6) -alkylene (C1-C6) -, heteroaryl (C3-C14) -alkylene (C1-C6) -, heterocycle (C3-C14) -alkylene (C1-C6) -; and wherein any alkyl, alkylene, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more members selected from the group consisting of halogen, oxo, -COOH, -CN, -NO2, -OH, -NRdRe, - NRgS (O) 2Rh, (C1-C6) alkoxy, aryl (C3-C14), haloalkyl (C1-C6) and aryloxy (C3-C14); wherein Rd, Re, Rg, and Rh are each independently selected from the group consisting of H, linear or branched (C1-C6) alkyl, (C3-C14) aryl (C1-C6) alkylene - optionally substituted, aryl ( Optionally substituted C3-C14), hydroxyalkyl (C1-C6), aminoalkyl (C1-C6), H2N-alkylene (C1-C6) -, optionally substituted cycloalkyl (C3-C6), heterocycloalkyl (C3-C14), heteroaryl (C3 -C14) optionally substituted, aryl (C3-C14) - alkylene (C1-C6) - optionally substituted, NR'R "C (O) -, and aryl (C3-C6) -cycloalkylene (C3-C14) -, or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, with the proviso that the compound according to Formula I is not 1-amine-2- (3- boronopropyl) carboxylic acid cyclohexane. |
| priorityDate | 2010-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 324.